| 1 |
Carrel AL, Myers SE, Whitman BY, Eickhoff J, Allen DB. Long-term growth hormone therapy changes the natural history of body composition and motor function in children with prader-willi syndrome. J Clin Endocrinol Metab 2010;95:1131-6.
DOI
|
| 2 |
Hoybye C, Thoren M, Bohm B. Cognitive, emotional, physical and social effects of growth hormone treatment in adults with Prader-Willi syndrome. J Intellect Disabil Res 2005;49:245-52.
DOI
|
| 3 |
Lo ST, Siemensma EP, Festen DA, Collin PJ, Hokken-Koelega AC. Behavior in children with Prader-Willi syndrome before and during growth hormone treatment: a randomized controlled trial and 8-year longitudinal study. Eur Child Adolesc Psychiatry 2015;24:1091-101.
DOI
|
| 4 |
Wolfgram PM, Carrel AL, Allen DB. Long-term effects of recombinant human growth hormone therapy in children with Prader-Willi syndrome. Curr Opin Pediatr 2013;25:509-14.
DOI
|
| 5 |
Eiholzer U. Deaths in Children with Prader-Willi Syndrome. Hormone Research in Paediatrics 2005;63:33-9.
DOI
|
| 6 |
Bakker B, Maneatis T, Lippe B. Sudden Death in PraderWilli Syndrome: Brief Review of Five Additional Cases. Hormone Research in Paediatrics 2007;67:203-4.
DOI
|
| 7 |
de Lind van Wijngaarden RF, Cianflone K, Gao Y, Leunissen RW, Hokken-Koelega AC. Cardiovascular and metabolic risk profile and acylation-stimulating protein levels in children with Prader-Willi syndrome and effects of growth hormone treatment. J Clin Endocrinol Metab 2010;95:1758-66.
DOI
|
| 8 |
Goldstone AP, Holland AJ, Hauffa BP, Hokken-Koelega AC, Tauber M. Recommendations for the diagnosis and management of Prader-Willi syndrome. J Clin Endocrinol Metab 2008;93:4183-97.
DOI
|
| 9 |
Festen DA, de Weerd AW, van den Bossche RA, Joosten K, Hoeve H, Hokken-Koelega AC. Sleep-related breathing disorders in prepubertal children with Prader-Willi syndrome and effects of growth hormone treatment. J Clin Endocrinol Metab 2006;91:4911-5.
DOI
|
| 10 |
Grugni G, Sartorio A, CrinoA. Growth hormone therapy for Prader-willi syndrome: challenges and solutions. Ther Clin Risk Manag 2016;12:873-81.
DOI
|
| 11 |
Diene G, Mimoun E, Feigerlova E, Caula S, Molinas C, Grandjean H, et al. Endocrine disorders in children with Prader-Willi syndrome--data from 142 children of the French database. Horm Res Paediatr 2010;74:121-8.
DOI
|
| 12 |
Craig ME, Cowell CT, Larsson P, Zipf WB, Reiter EO, Albertsson Wikland K, et al. Growth hormone treatment and adverse events in Prader-Willi syndrome: data from KIGS (the Pfizer International Growth Database). Clin Endocrinol (Oxf) 2006;65:178-85.
DOI
|
| 13 |
Cassidy SB, Schwartz S, Miller JL, Driscoll DJ. Prader-Willi syndrome. Genet Med 2012;14:10-26.
DOI
|
| 14 |
Lafortuna CL, Minocci A, Capodaglio P, Gondoni LA, Sartorio A, Vismara L, et al. Skeletal muscle characteristics and motor performance after 2-year growth hormone treatment in adults with prader-willi syndrome. J Clin Endocrinol Metab 2014;99:1816-24.
DOI
|
| 15 |
Hoybye C, Hilding A, Jacobsson H, Thoren M. Growth hormone treatment improves body composition in adults with Prader-Willi syndrome. Clin Endocrinol (Oxf) 2003;58:653-61.
DOI
|
| 16 |
Lo ST, Festen DA, Tummers-de Lind van Wijngaarden RF, Collin PJ, Hokken-Koelega AC. Beneficial Effects of LongTerm Growth Hormone Treatment on Adaptive Functioning in Infants With Prader-Willi Syndrome. Am J Intellect Dev Disabil 2015;120:315-27.
DOI
|
| 17 |
Deal CL, Tony M, Hoybye C, Allen DB, Tauber M, Christiansen JS. GrowthHormone Research Society workshop summary: consensus guidelines for recombinant human growth hormone therapy in Prader-Willi syndrome. J Clin Endocrinol Metab 2013;98:E1072-87.
DOI
|
| 18 |
Grugni G, Giardino D, CrinoA, Malvestiti F, Ballarati L, Di Giorgio G, et al. Growth hormone secretion among adult patients with Prader-Willi syndrome due to different genetic subtypes. J Endocrinol Invest 2011;34:493-7.
DOI
|
| 19 |
Eiholzer U, Nordmann Y, l'Allemand D. Fatal Outcome of Sleep Apnoea in PWS during the Initial Phase of Growth Hormone Treatment. Hormone Research in Paediatrics 2002;58(suppl 3):24-6.
DOI
|
| 20 |
Lindgren AC, Ritzen EM. Five years of growth hormone treatment in children with Prader-Willi syndrome. Swedish National Growth Hormone Advisory Group. Acta Paediatr Suppl 1999;88:109-11.
DOI
|
| 21 |
CrinoA, Fintini D, Bocchini S, Grugni G. Obesity management in Prader-Willi syndrome: current perspectives. Diabetes Metab Syndr Obes 2018;11:579-93.
DOI
|
| 22 |
Driscoll DJ, Miller JL, Schwartz S, Cassidy SB. Prader-Willi Syndrome [Internet]. Seattle (WA): GeneReviews®; c1998 [cited 2021 Feb 20]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK1330/.
|
| 23 |
Carrel AL, Myers SE, Whitman BY, Allen DB. Benefits of long-term GH therapy in Prader-Willi syndrome: a 4-year study. J Clin Endocrinol Metab 2002;87:1581-5.
DOI
|
| 24 |
de Lind van Wijngaarden RF, de Klerk LW, Festen DA, Duivenvoorden HJ, Otten BJ, Hokken-Koelega AC. Randomized controlled trial to investigate the effects of growth hormone treatment on scoliosis in children with Prader-Willi syndrome. J Clin Endocrinol Metab 2009;94:1274-80.
DOI
|
| 25 |
Reus L, Pelzer BJ, Otten BJ, Siemensma EP, van Alfen-van der Velden JA, Festen DA, et al. Growth hormone combined with child-specific motor training improves motor development in infants with Prader-Willi syndrome: a randomized controlled trial. Res Dev Disabil 2013;34:3092-103.
DOI
|
| 26 |
Corripio R, Tubau C, Calvo L, Brun C, Capdevila N, Larramona H, et al. Safety and effectiveness of growth hormone therapy in infants with Prader-Willi syndrome younger than 2 years: a prospective study. J Pediatr Endocrinol Metab 2019;32:879-84.
DOI
|
| 27 |
Yang X. Growth hormone treatment for Prader-Willi syndrome: A review. Neuropeptides 2020;83:102084.
DOI
|
webmaster
